Next Phase Newsletter

The firm is an East Coast-based early-stage fund founded in 2019. The firm is affiliated with, but separate from, a leading university leveraging the network of schools and 70,000 + alumni network to help their portfolio companies. The firm invests in technology-based companies in the pre-seed and seed stage, and while they prefer the companies have some revenue, they will invest in pre-revenue companies. The firm invests in several verticals, including SilverTech™ (Seniors and Tech), PropTech, Fintech, Cybersecurity HealthTech and AI/ML. The firm does not invest in therapeutics or medical devices. The firm invests in North America and in Israel, with check size between $50-150K into rounds with a pre-money valuation of $2-10M.

Within HealthTech, the firm invests in SilverTech™ and digital health. For digital health, the company is interested primarily in B2B models, but will invest in B2B2C as well. The firm has a special interest in Agetech, as one of the GPs is third generation senior living owner/operator.

The firm does not lead rounds, but is a very active investor alongside top-tier funds. Due to their strategic value,  they are asked to serve in an advisory capacity. The firm prides itself on being a valued strategic partner. The firm will invest in new or seasoned entrepreneurs, who have assembled exceptional teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm makes early-stage investments in cloud computing, E-commerce, AI, aerospace engineering, and biotechnology. The firm typically engages in seed to series A investment rounds. The firm is open to companies based around Seattle, Oregon, and is recently looking into the Greater Boston areas. The firm tends to be a co-investor.

The firm is most interested in the cross sector of IT and life sciences, especially in AI-driven healthcare technologies. Interested areas in include oncology, precision medicine, AI-enabled drug discovery and healthcare SaaS.

There is no specific requirement for the company and management team. The firm is open to working with both experienced and new entrepreneurs on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm with offices in Europe currently manages a fund that focuses on investments in Europe-based therapeutics and medical innovation. The firm invests in Europe, and typically allocates €5 to €12 million equity to each portfolio company, generally over several tranches.

The firm invests in therapeutics ventures. The firm is agnostic regarding technologies and indication areas and invests in companies with assets 12 months or less to the clinic, as well as assets in phase 1 or 2.  (i.e Series A and Series B)

Moreover, the firm is a company builder, identifying academic projects with potential for company creation. The company has developed a specific model of collaboration between the academic, the firm and an industrial to create companies.

The firm prefers to invest in companies that can present an exit opportunity in 3-5 years, usually through a pharmaceutical industry partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The corporate venture capital arm of a global science-based company active in health, nutrition and materials makes equity investments into seed and venture stage companies generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking to make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

The firm is looking for materials science companies in orthopedics and soft tissue repair. The firm also actively invests in human nutritional health, with a specific focus on companies active in personalized nutrition, and companies developing nutritional products. While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.

The firm highly values experience in a firms management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with relevant businesses of the parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A diversified, global, alternative asset manager with multiple offices across the globe has billions of dollars under management. The firm is invested equally in the private and public markets, and within the private markets, the firm seeks to invest across the entire private healthcare company lifecycle, from seed to cross-over. Initial check sizes can range from $5 – 50m and will largely depend on the stage of the company. With seed stage companies, the firm can invest $1-5m. In general, the firm ascribes to the approach of doubling the size of their prior round investment in each subsequent round (from Seed -> Series A -> Series B -> Series C -> IPO), subject to milestone achievement. The firm is currently focused on USA and Western European opportunities.

The firm’s primary investment focus is disruptive therapeutics-focused companies. The firm is most interested in genetic medicines (DNA, RNA, protein-targeted therapies including gene therapy, gene editing, oligonucleotides, and small molecule approaches), precision/targeted oncology (DNA damage repair/synthetic lethality, driver/resistance mechanisms), differentiated immunotherapies (gamma-delta T-cell-targeted, bispecific T-cell engagers, new efforts at drugging difficult checkpoints/targets), CNS disorders and autoimmune disorders (new targets of interest). The firm may consider therapeutics indications outside of CNS, oncology, and autoimmune disease on a much more selective basis. In terms of stage of development, the firm is open to pre-clinical opportunities from the lead optimization phase and beyond (discovery phase will be considered too early). The firm may consider opportunities outside of therapeutics including medical devices, diagnostics, tools and digital health, but will be much more selective.

The firm has no particular company or management team requirements. The firm is willing to lead rounds but can act as a follow-on – the firm may seek board representation when acting as the lead investor. The firm seeks to hold shares of their private company investments long after their successful IPO.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

The firm is a philanthropic venture firm established by the a family trust in 2009 to accelerate the development of promising technologies for the diagnosis and treatment of cardiovascular and neurovascular disease through targeted investments. The firm makes 4-5 investments each year of approximately $1 million into privately-held companies worldwide at both the seed and early venture stages. The firm operates under an evergreen structure and has made 47 investments to date. 

While the firm is focused on cardiovascular, neurovascular and metabolic diseases (e.g., diabetes, dyslipidemia and obesity), the firm invests across all technology sectors including biotech, medtech, diagnostics, and regenerative medicine. Broadview looks to invest in companies where its investment will help move the company to a value inflection point necessary for the next and larger financing round. 

The firm invests in technologies that have the potential for a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including size and likely sources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The company is a publicly traded company focused on oncology therapeutics. The firm is seeking therapeutic opportunities in the oncology space. The firm is looking to partner and collaborate as well as in-license, but is primarily seeking partnerships. The firm seeks assets that have at the very least cellular proof of concept, but prefers companies to have some animal data or are approaching pre-IND studies. The firm is also willing to partner with unique and differentiated drug discovery platform companies. The firm will partner globally, but primarily partners with US and Europe-based companies. 

The firm is interested only in oncology and immuno-oncology assets in high unmet tumor indications including RCC and HCC. For modality, the firm is interested only in small molecule and biologics. The firm is willing to consider therapeutics targeting both solid and liquid tumors. The firm will also partner with drug discovery companies, such as those using AI-based technologies to identify new therapeutic biology, as well as platform companies. 

The firm will only partner with companies that have a strong IP position and a clear differentiating discovery and development strategy. The firm looks for startups with unique “First-in-Class” therapeutics and platforms. 

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.